Home Mf Research Tata Nifty Midsmall Healthcare Index Fund Regular Plan Growth
Tata Mutual Fund

Tata Nifty MidSmall Healthcare Index Fund - Regular Plan - Growth

Fund House : Tata Mutual Fund
Overview
Returns
Portfolio
SIP Calculator
Analysis
Peer Comparison
Fund Family
Scheme Details
-
-
  • 1W
  • 2W
  • 1M
  • 3M
  • 6M
  • 1Y
  • SI
NAV (as on 2025-06-03)
12.06 -0.20%
Fund Size (Total Assets)
-
Expense Ratio (Regular)
1.09%
Expense Ratio (Direct)
0.34%
SIP Returns
Period Invested for ₹1000 SIP Started on Investments Latest Value Abs. Returns
One Week 2025-05-27 ₹1,000.00 ₹996.83
-0.32 %
Two Week 2025-05-19 ₹1,000.00 ₹992.40
-0.76 %
1 Month 2025-05-05 ₹1,000.00 ₹1,004.34
0.43 %
Three Months 2025-03-05 ₹3,000.00 ₹3,104.33
3.48 %
Six Months 2024-12-05 ₹6,000.00 ₹5,998.72
-0.02 %
One Year 2024-06-03 ₹12,000.00 ₹12,401.00
3.34 %
Since Inception 2024-04-26 ₹14,000.00 ₹14,628.46
4.49 %
Portfolio Summary
Company Name Sector Sector Type Nav(in %)
Poly Medicure Ltd. Healthcare Equipment & Supplies Equity 1.67
Max Healthcare Institute Ltd. Healthcare Services Equity 13.48
Fortis Healthcare Ltd. Healthcare Services Equity 5.17
Syngene International Ltd. Healthcare Services Equity 2.90
Dr. Lal Path Labs Ltd. Healthcare Services Equity 2.24
Krishna Institute Of Medical Sciences Ltd. Healthcare Services Equity 2.07
Global Health Ltd. Healthcare Services Equity 2.04
Narayana Hrudayalaya Ltd. Healthcare Services Equity 1.68
Rainbow Childrens Medicare Ltd. Healthcare Services Equity 1.17
Aster Dm Healthcare Ltd. Healthcare Services Equity 1.10
Metropolis Healthcare Ltd. Healthcare Services Equity 1.07
Lupin Ltd. Pharmaceuticals & Biotechnology Equity 9.13
Aurobindo Pharma Ltd. Pharmaceuticals & Biotechnology Equity 7.98
Alkem Laboratories Ltd. Pharmaceuticals & Biotechnology Equity 5.27
Glenmark Pharmaceuticals Ltd. Pharmaceuticals & Biotechnology Equity 4.34
Mankind Pharma Ltd. Pharmaceuticals & Biotechnology Equity 3.70
Laurus Labs Ltd. Pharmaceuticals & Biotechnology Equity 3.61
Ipca Laboratories Ltd. Pharmaceuticals & Biotechnology Equity 3.48
Biocon Ltd. Pharmaceuticals & Biotechnology Equity 3.18
Abbott India Ltd. Pharmaceuticals & Biotechnology Equity 2.99
Gland Pharma Ltd. Pharmaceuticals & Biotechnology Equity 2.92
J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceuticals & Biotechnology Equity 2.72
Suven Pharmaceuticals Ltd. Pharmaceuticals & Biotechnology Equity 2.50
Natco Pharma Ltd. Pharmaceuticals & Biotechnology Equity 2.44
Ajanta Pharma Ltd. Pharmaceuticals & Biotechnology Equity 2.32
Glaxosmithkline Pharmaceuticals Ltd. Pharmaceuticals & Biotechnology Equity 2.19
Piramal Pharma Ltd. Pharmaceuticals & Biotechnology Equity 2.12
Granules India Ltd. Pharmaceuticals & Biotechnology Equity 1.69
Alembic Pharmaceuticals Ltd. Pharmaceuticals & Biotechnology Equity 1.28
Sanofi India Ltd. Pharmaceuticals & Biotechnology Equity 1.17
Sanofi Consumer Healthcare India Ltd. Pharmaceuticals & Biotechnology Equity 0.42
SIP Calculator
Risk Ratios
Standard Deviation
-
Beta
-
Sharpe Ratio
-
Lock In Period
-
Residual Maturity
-
Standard Deviation:
Standard deviation numbers measure the variability or volatility of a fund's returns over a specific time period (often 3 years).
  • Low standard deviation = Stable, predictable returns → Suitable for conservative investors seeking stability.
  • High standard deviation = High volatility, more risk → Be cautious, suitable for risk-tolerant investors who can handle fluctuations.
Beta:
Beta measures a fund's volatility about the market or a benchmark. A lower beta means the fund's performance is less sensitive to market movements, making it more predictable compared to the market.
  • Low beta = Less sensitive to market changes → Great for investors with less market exposure.
  • High beta = More sensitive to market changes → Better for aggressive investors who seek higher returns but can handle market risks.
Sharpe Ratio:
The Sharpe Ratio measures how much return a fund has made compared to the risk it carries. A higher Sharpe ratio indicates better returns relative to the risk taken, meaning the fund delivers more efficiently.
  • A higher Sharpe ratio indicates better risk-adjusted returns → Look for funds with higher ratios for better return efficiency.
  • Use it to compare different funds' efficiency in generating returns relative to the risk taken.
Lock-In Period:

India's "lock-in period" in mutual funds encourages long-term investment, particularly in tax-saving schemes preventing redemption or selling of units.

Lock-in times for various investment types

  • Most ELSS mutual fund holders hold for 3 years.
  • Tax savings FDs lock in for 5 years.
  • The lock-in period for 8% Government of India bond investment is 6 years.
  • ULIPs must be locked in for 5 years.
  • The average hedge fund holding period is 30-90 days.
  • The average PPF investor holds onto their money for 15 years.
Residual Maturity:

Residual maturity is the remaining time until a security reaches its maturity date. It is an important factor for investors to consider when evaluating the risk associated with an investment.

There are two different types of residual maturity.

  • Short-term residual maturity: This occurs when a security has less than a year left on its maturity.
  • Long-term residual maturity: This occurs when a security has more than a year left on its remaining maturity.
Scheme Details
  • Fund manager(s) : Kapil Menon (20 years),
  • Expense ration regular : 1.09
  • Expense ration direct : 0.34
  • Launch date : -
  • Benchmark : -
  • Min SIP amount : -
  • Max SIP amount : -
  • Min investment amount (one time- first time) : ₹100.00
  • Type : others
Exit load
0.25%

FAQs

Is a Mutual Fund with a Lower NAV Better?
What Are the Charges in Mutual Fund Investments?
What Are the Tax Benefits of Mutual Funds?
Is It a Good Time to Invest in Mutual Funds?
What Is the Difference Between Dividend and Growth Plans?
Should I Invest in Infrastructure Funds?
What Are Sector-Specific Funds/Schemes?
What Happens If I Miss an SIP Payment?
How Can I Compare Different Mutual Funds?